Physician profile
David R Drosick
NPI 1699768499
$4,574.84
in general payments reported to CMS, 2019-2025
42 companies · $2,074 in 2025
The $2,074 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $50.78 · 2021: $171 · 2023: $490 · 2024: $1,666 · 2025: $2,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,351 · Long Term Medical Supply Or Device Loan: $1,863 · Education: $16.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.76 |
| Long Term Medical Supply Or Device Loan | $1,863.04 |
| Education | $16.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,170.80 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $209.81 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $192.61 | 2024-2025 | |
| Pfizer INC. | $185.58 | 2019-2025 | |
| Emd Serono, INC. | $147.39 | 2023-2025 | Tepmetko |
| Celgene Corporation | $141.36 | 2021-2024 | Reblozyl, Pomalyst |
| Rigel Pharmaceuticals, INC. | $129.27 | 2019-2025 | Gavreto, Rezlidhia, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $122.00 | 2020-2025 | Opdivo |
| Gilead Sciences, INC. | $120.25 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $94.12 | 2023-2025 | Enhertu |
| Lilly USA, LLC | $67.44 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Aveo Pharmaceuticals, INC. | $64.54 | 2024-2025 | |
| Stemline Therapeutics INC. | $61.34 | 2023-2025 | Orserdu |
| Sun Pharmaceutical Industries INC. | $61.17 | 2024 | |
| Incyte Corporation | $58.95 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Drosick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.